Higher expression of ORC6 was significantly associated with worse prognosis in DSS for patients with 17 types of cancers (e.g., ACC, LGG and PRAD), while lower expression of ORC6 was only negatively correlated with the prognosis of COAD, OV, and THYM (Supplementary Fig. 5). Here, ORC6 is linked to prostate adenocarcinoma.